Fig. 1 · Structure
Documents & Downloads
Ladiratuzumab vedotin
LIV-1-Targeting ADC
Ladiratuzumab vedotin is an antibody-drug conjugate (ADC) targeting LIV-1, with an IC50 of 5.6 nM. This therapeutic agent comprises a humanized IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE) via a protease-cleavable linker, facilitating the delivery of the cytotoxic agent directly to the target cells. Ladiratuzumab vedotin promotes immunogenic cell death, stimulating an immune response, and is utilized in research focused on breast cancer treatment and therapeutic strategies.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 1629760-29-7 |
| Applications | LIV-1-Targeting ADC |
| Molecular Weight | 152224 (average) |
| Synonyms | SGN-LIV1A |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.